Skip to main content

Evommune, Inc Investor Event Transcript, Nov 18, 2026

Evommune, Inc. (EVMN)

Evommune reports $290 million in cash, funding its pipeline through the second half of 29. Its 330-patient oral migraine trial reads out in the second half of 2027. AI summary

Investor Event Transcript 2026-11-18 For: 2026-12-31
Added on November 18, 2026

Conference Transcript - EVMN 2026-11-18

Operator

Good afternoon, everyone. Welcome to the 2026 Jeffries Healthcare Conference. Today, we're very pleased to have Ivo Mune and Luis Penna, CEO. Thank you very much.

Luis Peña, CEO

Thanks. Thank you, and thank you to Jeffries for having us, and for all of you that are here. We're excited to talk about Evamune today. Evamune is a company that's been around for six years now, and our focus since the inception has been on developing novel assets for chronic inflammation and to build a robust pipeline around that. So you have the normal forward-looking statements and disclaimers. So in those six years now, we have built what is now a very robust pipeline with a number of novel targets and multiple data readouts over the next couple of years. Our lead, EVO301, which is an ILA team binding protein, is about to initiate studies in 27, both in atopic dermatitis and ulcerative colitis. The atopic dermatitis trial is going to be a robust Phase 2B study with three different arms versus placebo. That'll start mid-next year and readout in 28. This follows after some pretty exciting Phase 2A data, which I'll talk about later. We're also going to initiate a Phase 2A trial in ulcerative colitis in the first half of 27 that'll also readout in 28. The second program that's in Phase 2 is an MRGPRX2 oral inhibitor. This is currently enrolling in a robust 330-patient migraine trial, and that study is going to read out in the second half of 2027. We're also excited to start introducing and going into the clinic with two different orals. One is an oral Vav1 molecular glue degrader that we just in license. We announced this last week. We have a great collaboration with HiNova, a company from China, with an exquisite molecule, and we're imminently starting a phase one trial. They actually are going to run the phase one trial, and then we will be in charge of global development. Vav1 is a very exciting target. That we'll talk about in more detail as an oral, very potent molecule, and that will start the Phase I trial, and we're going to have that data available with biomarker data, including possibly some RA patient arms in the first half of 27. And then, last but not least, we have an oral TLR7-8 inhibitor. You probably have heard about some of the exciting beeline data in SLE recently. Unfortunately, we have our own molecule that's very potent that will enter the clinic in the first half of next year, and then it will read out in 27. So multiple clinical data sets over 27 and 28. We're well-funded. We have raised capital at the right times with positive data sets, and so we have $290 million in cash that take us through the second half of 29. So, enough funding for all of these readouts so that we don't have to raise capital and we can raise capital and be opportunistic around positive data going forward. So, robust pipeline that we're very excited about. So let's start to talk about each program independently. Our lead, as I mentioned, headed in two phase two studies is an IL-18 binding protein. We love this molecule. IL-18 is a molecule that's ubiquitously involved in chronic inflammation across a number of indications, so much so that there is a naturally occurring binding protein of the molecule. The problem with the wild-type binding protein is that it gets cleared very rapidly so that you would have to dose it three times a day. But there is a very exciting molecule that we have, which is the IL-18 binding protein that's bound to a fragment of antibody that allows it to bind the albumin, and that increases the half-life such that we can dose it likely once a month once we get into the maintenance We've already shown very exciting data here. As you see on the left here, we did a phase 2a study in atopic dermatitis, and what you're seeing there is a percent change of EZ versus placebo. This was with really suboptimal dosing. We dosed at day zero and day 28 with a 5 mg per kg dose, and the reason we didn't dose further is because we didn't have tox coverage, But we wanted some initial readout on the IL-18. And with only dosing out to a month, at week 12, we saw some pretty impressive data, which was that we had a mid-30% separation in active over placebo. That compares very well historically, even though it's tough to do comparison to apples to apples across studies, but it compares very well to any of the current biologics that are out there, including Dupixin and EbGlis, which we actually developed into phase three in our previous life at Dermira. So very exciting data, and we are really looking forward to dose optimizing. So when we talk about our phase 2B study that we're going to start mid-next year, and we're scaling up our manufacturing for that, we already have a sub-Q formulation ready to roll. We're going to be looking at three different arms of active versus placebo. We're going to look at two Q four-week arms that are dosed out to 16 weeks. And then we're also going to look at a Q2 week arm. In that induction phase out to 16 weeks, it's very important to be aggressive. With dosing, historically, biologics that have loading doses and aggressive dosing initially through week 16 do very well. And then we have a long enough half-life that as we go into the maintenance phase of phase three, we should be able to do quite well. So we're really looking forward to initiating that trial, and along with the strong efficacy results that we saw in the Phase 2A study, it's been exquisitely well-tolerated, so there's no conjunctivitis with the drug, and so we think that that'll do well and serve well as really first-line therapy, as a monotherapy in atopic dermatitis going forward. So that starts in mid-27. We're also going to start an ulcerative colitis trial with this drug, with our IV drug, actually, so we can start to do life cycle management early, and both of those we'll read out in 28. So great opportunity, and we're certainly excited about this biologic. Second in line, we have a molecule in Phase IIb now. This is an oral MRGPRX2 inhibitor. It's an interesting target in that it's expressed both in mast cells as well as in neurons. For the skin, it's more sensory neurons. It's in the trigeminal neurons in the meningeal space. We initiated this migraine study some time ago. It's enrolling quite well, and we're testing two doses of this oral MRGPRX2 inhibitor, 25-milligram BID dose and a 50-milligram BID dose versus placebo. Pretty robust trial, 330 patients. That is going to read out second half of next year. The primary endpoint will be the mean change from baseline and monthly migraine days, and we are enriching for a more severe migraine population, which you normally do in these Phase II trials. Even at 330 patients, it's actually somewhat of a limited sample size for migraine, but we're excited. And there's a number of data sets, both preclinically and clinically, to suggest that this could work quite well in migraine. Preclinically, you can actually induce multiple ligands that drive mast cell activation, as well as neuropeptide activation in neurons. This is PACAP, VIP, and Substance P. All of these have shown migraine induction in mouse models, excuse me, and then also they have been infused in humans. So these three different ligands have been infused in migraine patients, and they all induce migraine. And what was exciting in the last couple of years, LUMBEC, which you might be familiar with, has a PACAP monoclonal that they dose patients with, and they were able to show a reduction in migraine days over a placebo. So, pretty exciting data. We believe it's validation that by blocking these ligands, or at least by blocking the X2 receptor from these ligands, you have an opportunity to have efficacy in migraine patients. With PACAP, X2 is not the only receptor, and, for example, PAC-1 is another receptor. Amgen had an antibody versus Pac-1 that did not show efficacy, so the evidence suggests that X2 may be an important receptor there, so we think that this could be an important addition for migraine patients, and this robust trial will read out second half of next year. Thank you. So, um, third, um, uh, third molecule or program in the pipeline that we are going into the clinic with imminently, we just announced, uh, very recently, this is a collaboration with HiNova. HiNova is a company that is in China and, um, have, uh, developed a number of very exciting molecules. This is a VAB1 molecular glue degrader. It is really the only way to really go after this target. It's, to this point, been undruggable unless you degrade it. And it's a very exciting target in that it impacts both T and B cell signaling, antigen signaling, but does not hit the majority of the cytokines that JAK inhibitors do. And the goal there would be to have some pretty aggressive immunosuppression, but without the cardiovascular effects that you see with the JAKs. And so that's pretty exciting to think about because that really opens up the world of multiple indications that you see with the over 10 JAKs now that are out there clinically and commercially. So very established market, and we think that this Vav1 target has a great opportunity. Of course, we're going to have to prove that clinically, but our expectation is that we'll see efficacy across multiple indications, that we're not going to see, we're going to be able to separate the cardiovascular effects that you see with the Jax, and that will really open up all of those indications to the Vav1 field. Novartis is already out there. You probably saw a deal with Monterosa that was pretty significant for a preclinical asset. They paid, I think, $150 million up front for it, validating that excitement in the target. We actually had a much more modest up front for it. We were pretty aggressive in terms of convincing HiNova that we should be a great partner for them, That we move quickly, and they're actually not only allowed us to have a more modest up front, but they're actually sharing some of the development costs. We are in charge of global development for this program and asset, but we think Pynoba is a great partner, and they'll be, as I said, they'll be paying for part of the development. This molecule is significantly more potent than the monorosa molecule, and the chemistry is one novel in that there's good freedom to operate given that it's a very novel IP. So a lot of the preclinical assets that are out there, and by the way, we've been looking now for about two years into this target and have had 14 molecules in our hands that we've compared directly, and this was by far the one we liked the most, one from the perspective that it's the most potent, it's the cleanest, it meets all the Lipinski rules, it's very soluble, but also the IP is most distinct, so it's exactly where we want to land. So when we saw it, we had it in our hands, we immediately knew that we wanted to go after it aggressively. So it's a great collaboration. We're very excited about it. The U.S. IND is already open. It's imminent in terms of starting the phase one study. We will do the typical single ascending dose, multiple ascending dose study. There will be an opportunity for us to measure biomarkers at the end of that, and that's going to read out in the middle of the next year. And we may add a couple of arms, of patient arms to that study on the multiple ascending dose to higher doses. Our initial indication, even though many indications are available, and Novartis initially is in Sjogren's, and PSA, will be RA. There is a good opportunity for an oral and RA, especially with a novel target like this. We have a good ability to do trials, both in the U.S. and externally, and this is the target that should do quite well there. That said, it should be a target that's exquisite for life cycle management and many other indications. We will initiate that RA study in the second half of 27, so that'll be exciting to roll quickly into that study. And, you know, given how Sjogren's is a bit tough to enroll, we wouldn't be surprised if we were able to catch up with this program. So, yeah, exciting entrant into our pipeline. And then last but not least, we have a TLR7-8 antagonist for autoimmune disease, highly potent molecule. This is a QD oral drug. There's been some very, very recent data which showed significant efficacy in SLE, as you all know, a very, very tough indication. And they were able, Beeline showed this data, it was very well received, where you had a really incredible efficacy in SRI-4 scores versus placebo in the mid-60s versus placebo in the mid-30s. So it's really been both genetically but clinically validated. And the TLR7 itself is interesting that it blocks type 1 interferon as well as autoantibody-producing B cells, allowing it to have a broad enough profile to work in an indication like lupus. And so we will be entering the clinic the first half of next year. Very potent molecule. It's clean from a safety pharmacology perspective. We don't see it lighting up any of the safety pharmacology studies that you normally do early on. Again, very well-behaved molecule in terms of meeting all the Lipinski rules, highly soluble, and very distinct IP from anything that's out there. So excited about this. We will put it into the Phase I study. Again, biomarkers are going to be important given that you already have robust clinical efficacy here. If we show a reduction in biomarkers with this molecule, then we will be in play, and of course we'll be measuring the safety as well, and that data should be available in the second half of 27. So, you know, robust pipeline, and we even have molecules behind this. We have STAT6 inhibitors and degraders, but just focusing on what we have clinically. So, again, to focus on catalyst-rich outcomes and to summarize, in the first half of 27, we'll initiate the Phase 2A ulcerative colitis trial in 301. We'll initiate phase 1 studies with our Vav1 and MRG, excuse me, and TLR7-8 inhibitors. In mid-27, we'll initiate our phase 2B study in atopic dermatitis, and then have our healthy volunteer biomarker data available for our Vav1 asset. In the second half of 27, we'll have our phase 2B data set in migraine with our oral MRGPRX2 inhibitor. We'll initiate the RA study with our VAB1 program, and then we'll have the Phase I healthy volunteer data with our TLR78, and then in 28, we'll have the ulcerative colitis and AD data with our IL-18 binding protein, and then we'll initiate Phase II with our TLR78, so incredibly robust data sets, a lot of work to do. Thank you. I'm a chef. I love to cook, and when I'm putting broad menus together, I'm thinking, man, this is going to be a lot of work. So we've got a lot of work here, but we've got a great team to do it collectively. The team that is leading this has 28 approved NDAs under our belt that we led, so a lot of experience here, a lot of experience in the company, and we're looking forward to driving this robust pipeline forward. So thank you all for your time, and given that we have a little time left here, I'm happy to take any questions if there are any.

Operator

Thank you. Okay.